How Wazoku Crowd Solved Challenges in Gastroenterology

Innovation in Gastrointestinal Research with the Wazoku Crowd

Gastroenterology encompasses a wide range of complex and chronic diseases affecting the gastrointestinal (GI) tract, such as inflammatory bowel diseases (IBD), GI cancers, and liver and pancreatic disorders. Traditional treatments often focus on symptom management rather than addressing the underlying causes, leaving a critical need for more innovative, curative solutions. This is where Wazoku’s Open Innovation platform comes into play, leveraging the collective expertise of a global network of solvers to uncover novel treatment approaches and solutions.

By facilitating collaboration, Wazoku helps leading organizations in the health and life sciences industry explore breakthrough ideas, such as microbiota modulation, epigenetic interventions, gene therapy, and metabolic solutions, that push the boundaries of current GI treatments. These efforts are paving the way for more effective therapies and potential cures.

Below are some of the challenges that the Wazoku Crowd has successfully helped solve in the field of gastroenterology.

Gastroenterology Innovation Challenge: Novel Treatment Approaches to Cure Inflammatory Bowel Diseases

A leading organization sought innovative proposals to cure Crohn’s disease and ulcerative colitis by focusing on novel mechanisms that directly target the pathogenesis of inflammatory bowel diseases (IBD). They aimed to explore ideas beyond traditional immunosuppression, such as microbiota modulation, metabolic interventions, genetic and epigenetic targets, vaccines, gene therapy, and small molecule compounds.

Inflammatory Bowel Diseases are chronic idiopathic inflammatory disorders affecting the gastrointestinal tract. Crohn’s disease and ulcerative colitis are the major types of IBD, believed to be triggered by environmental factors in genetically susceptible individuals. Existing treatments primarily focused on short-term symptom management—reducing inflammation and flare-ups to improve patients’ quality of life—or long-term disease modification to limit progression. However, the organization aimed to advance scientific understanding of IBD initiation to enable a permanent cure.

The Seeker specifically sought solutions for this Gastroenterology Innovation Challenge that met the following requirements:

• Novelty: Approaches not widely reported in the literature that address the root causes of IBD.
• IBD-Specificity: Solutions uniquely relevant to IBD pathogenesis rather than general immunological conditions.
• Approaches of Interest: Focus on epigenetics, new molecular targets, microbiota, metabolism, gene-delivery methods, and other out-of-the-box ideas.

Submissions required a detailed description of how the approach addresses the root cause of IBD, a succinct scientific rationale, supporting information or references, and a willingness to engage in further collaboration.

How the Wazoku Crowd Solved It

By tapping into the vast and diverse expertise of the Wazoku Crowd, we successfully addressed this complex Gastroenterology Innovation Challenge for our client in the Health and Life Sciences industry. Our global network of solvers brought fresh perspectives and specialized knowledge, leading to a range of innovative and promising solutions.

The submissions we received were both novel and specifically tailored to address the pathogenesis of IBD. Solvers proposed a variety of approaches, including:

• Epigenetic Interventions: Ideas focusing on modulating epigenetic regulators to correct aberrant gene expression associated with IBD susceptibility genes.
• Microbiota Modulation: Innovative therapies aimed at restoring the balance of gut microbiota, thereby reducing inflammation and addressing one of the root causes of IBD.
• Advanced Gene Therapies: Proposals involving cutting-edge gene delivery techniques designed to correct genetic defects linked to IBD, targeting the disease at its genetic foundation.
• Metabolic Interventions: Approaches that explore altering metabolic pathways to reduce inflammation and promote healing of the gastrointestinal tract.
• Novel Molecular Targets: Identification of new molecular targets unique to IBD pathogenesis, offering potential for the development of new therapeutic agents.

These solutions stood out for their originality and their potential to be developed into effective cures for IBD. The collaborative environment fostered by the Wazoku platform enabled constructive dialogue between solvers and the client, allowing for the refinement of ideas and setting the stage for potential research partnerships.

Through the Wazoku Crowd, our client gained access to a wealth of innovative ideas that directly addressed the underlying causes of IBD with the potential to lead to a permanent cure. This successful collaboration highlights how engaging a global network of experts can accelerate problem-solving in the Health and Life Sciences industry. By transforming the way challenges are approached, we helped pave the way for advancements that could significantly improve the lives of those affected by IBD.

Learn more about this challenge and others on Wazoku’s Open Innovation Challenge Centre.

Gastroenterology Innovation Challenge: In Vitro System to Assess Gastrointestinal Toxicity

The Seeker aimed to find an innovative in vitro model to assess and understand gastrointestinal (GI) toxicity, particularly related to the rapid cell turnover in the GI tract and the adverse effects of cancer chemotherapy. The goal was to develop a translationally relevant model capable of predicting the onset and recovery from GI toxicity, especially in the context of combination therapies involving radiation therapy and inhibitors of DNA damage repair pathways (DDRi).

The GI tract is notably sensitive to radiation therapy-induced toxicity. Oncology agents often induce GI toxicities due to their effects on the rapidly dividing stem cell compartment in the intestinal crypts. While the GI system is resilient and capable of recovery if drugs are administered with appropriate scheduling, defining the optimal drug schedule for oncology combinations is challenging. Traditional preclinical in vivo models provide some insights, but the Seeker wanted to explore the use of in vitro models to investigate GI toxicity onset and recovery more effectively.

They specifically sought solutions that met the following requirements:

• Human Tissue Usage: Preferably using human tissue, though rat or dog tissue (species typically used in preclinical toxicity studies) was acceptable. Mouse tissue was less desirable but satisfactory.
• Stability in Culture: The tissue preparation used in the method needed to be stable in culture for a minimum of 14 days, preferably longer.
• Physiologically Relevant Readouts: The assay should provide a physiologically relevant functional readout (e.g., Transepithelial Electrical Resistance or TEER). The ability to provide insight into the affected cell types was considered a bonus.
• Quantifiable Assay Readout: The assay readout needed to be quantifiable to establish IC50 values and have sufficient throughput to test multiple compounds per experiment.

Submissions were required to include a detailed description of the test protocol, experimental proof-of-concept data quantifying GI toxicity (preferably in response to a clinically relevant radiation exposure), documented access to a radiation source, and a rationale explaining why the proposed system would effectively assess GI toxicities of combination therapies that include radiotherapy.

How the Wazoku Crowd Solved It

By leveraging the collective expertise of the Wazoku Crowd, we successfully addressed this intricate Gastroenterology Innovation Challenge for our client in the Health and Life Sciences industry. Our global network of solvers brought together diverse perspectives and specialized knowledge, resulting in a range of innovative and practical solutions.

The submissions we received were both novel and aligned with the Seeker’s specific requirements. Solvers proposed various approaches, including:

• Advanced 3D Intestinal Models: Development of three-dimensional intestinal organoid cultures derived from human tissue, capable of mimicking the complex architecture and functionality of the GI tract. These models demonstrated stability in culture beyond 14 days and provided physiologically relevant readouts.
• Microfluidic Systems (“Gut-on-a-Chip”): Utilization of microfluidic devices that simulate the dynamic environment of the GI tract, allowing for controlled exposure to radiation and drugs. These systems offered high-throughput capabilities and quantifiable readouts such as TEER measurements.
• Co-Culture Systems: Implementation of co-culture models incorporating multiple cell types found in the GI tract, providing insights into cell-type-specific responses to toxicity. This approach enhanced the physiological relevance of the assay and allowed for more comprehensive toxicity assessments.
• Innovative Readout Techniques: Introduction of novel assay readouts, such as real-time monitoring of cellular metabolic activity or the use of specific biomarkers indicative of GI toxicity onset and recovery.

These solutions stood out for their ability to meet the Seeker’s requirements while offering scalability and potential for integration into existing research workflows. The collaborative platform facilitated constructive dialogue between solvers and the Seeker, enabling refinement of proposals and alignment with the project’s objectives.

Through the Wazoku Crowd, the Seeker accessed a wealth of innovative ideas that addressed the challenges of assessing GI toxicity in vitro. This successful collaboration underscores the value of engaging a global network of experts to accelerate problem-solving in the Health and Life Sciences industry. By transforming traditional approaches to such challenges, we contributed to advancements that could enhance the development of safer and more effective oncology treatments.

Learn more about this challenge and others on Wazoku’s Open Innovation Challenge Centre.

Gastroenterology Innovation Challenge: Delivery of Biomolecules to the Gastrointestinal Tract

The Seeker was in search of innovative technologies for the oral delivery of large, hydrophilic biomolecules, such as proteins and peptides, through the gastrointestinal (GI) tract. The goal was to overcome the poor bioavailability of these molecules and eliminate the need for invasive administration methods like injections. The challenge was open to improvements on existing technologies, adaptations from other non-invasive delivery methods, or entirely new technologies.

Oral delivery is typically the preferred route of administration due to its convenience and patient compliance. However, delivering large biomolecules orally presents significant challenges due to their high molecular weight, hydrophilicity, poor cell membrane permeability, instability in the gut environment, and susceptibility to enzymatic degradation. Despite intense research and development efforts over the years, a consistently efficacious platform for the oral delivery of biomolecules had not been established.

The Seeker specifically sought solutions for this Gastroenterology Innovation Challenge that met the following requirements:

• Enhanced Absorption Without Loss of Activity: The proposed solution must improve the absorption and delivery of biomolecules via the GI tract without compromising their biological activity.
• Platform Applicability: Ideally, the solution would be a platform technology applicable to a range of large, poorly permeable, hydrophilic biomolecules such as peptides.
• Scalability and Manufacturability: The solution must be amenable to large-scale manufacturing, using affordable and widely available materials, without incurring prohibitive development costs.
• Safety and Biocompatibility: The method must not involve toxic chemistries or materials that would impede its use in humans.
• Freedom to Practice: The solution should offer the Seeker the freedom to practice or be available for potential licensing, without third-party patent restrictions on specific equipment or materials.

Submissions were required to include a detailed description of the proposed delivery technology, a rationale addressing each of the solution requirements, supporting data or evidence of success, and an indication of the solver’s interest in potential partnership opportunities.

How the Wazoku Crowd Solved It

By harnessing the collective expertise of the Wazoku Crowd, we successfully addressed this complex Gastroenterology Innovation Challenge for our client in the Health and Life Sciences industry. Our global network of solvers brought diverse perspectives and specialized knowledge, resulting in a range of innovative and practical solutions.

The submissions we received were both novel and aligned with the Seeker’s specific requirements. Solvers proposed various approaches, including:

• Advanced Formulation Techniques: Development of novel formulations that protect biomolecules from degradation in the GI tract, enhance their permeability across the intestinal lining, and maintain their biological activity.
• Nanoparticle Delivery Systems: Utilization of biocompatible nanoparticles or nano-carriers designed to encapsulate biomolecules, facilitating their transport through the GI tract and absorption into systemic circulation.
• Chemical Modification Strategies: Introduction of temporary chemical modifications to biomolecules to improve their stability and permeability, which can be reversed after absorption to restore their original structure and function.
• Mucoadhesive Technologies: Implementation of delivery systems that adhere to the mucosal lining of the GI tract, increasing the residence time of the biomolecules and enhancing absorption.
• Permeation Enhancers: Identification and use of safe permeation enhancers that temporarily modulate tight junctions between epithelial cells, allowing larger biomolecules to pass through without causing long-term damage.

These solutions stood out for their potential to enhance the oral bioavailability of biomolecules while meeting safety and scalability requirements. The collaborative environment fostered by the Wazoku platform enabled constructive dialogue between solvers and the Seeker, allowing for the refinement of ideas and alignment with the project’s objectives.

Through the Wazoku Crowd, the Seeker accessed a wealth of innovative ideas that addressed the challenges of delivering large biomolecules orally. This successful collaboration highlights the value of engaging a global network of experts to accelerate problem-solving in the Health and Life Sciences industry. By transforming traditional approaches to such challenges, we contributed to advancements that could potentially improve patient outcomes by enabling more convenient and less invasive therapeutic options.

Learn more about this challenge and others on Wazoku’s Open Innovation Challenge Centre.

Wazoku Open Innovation

Wazoku’s Open Innovation platform has proven to be a powerful tool for solving complex challenges. By bringing together a global community of solvers, Wazoku helps leading organizations in the Health and Life Sciences industry tackle their toughest problems, drive innovation, and improve patient outcomes.

Whether through cutting-edge technologies like AI, precision medicine, or patient-centered research, Wazoku Crowd continues to push the boundaries of what’s possible in healthcare innovation.

Interested in driving innovation for your organization?

Run your own challenge and unlock the power of global collaboration to solve your toughest problems.

Explore